Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.35 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.35 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249853 | 0.76 | GPR3 (0.32) | GPR3 | |
| SCHEMBL2409495 | 0.73 | CYP2A6 (0.33) | GPR3CYP1A2ALDH1A1SMN1; SMN2CASP1 | |
| Benzonaphthyridine SCHEMBL29600756 | 0.72 | GPR3 (1.00) | GPR3LMNAHTTLCKMAP2K3 | |
| Benzonaphthyridine SCHEMBL51197 | 0.72 | GPR3 (1.00) | GPR3LMNAHTTLCKMAP2K3 | |
| Benzonaphthyridine SCHEMBL30897319 | 0.72 | GPR3 (1.00) | GPR3LMNAHTTLCKMAP2K3 | |
| SCHEMBL4408 | 0.72 | KDM4E (0.57) | GPR3LMNACYP1A2KDM4EALDH1A1 | |
| SCHEMBL26597 | 0.72 | KDM4E (0.57) | GPR3LMNACYP1A2KDM4ESMN1; SMN2 | |
| SCHEMBL4824194 | 0.71 | HPRT1 (0.35) | CYP1A2ALDH1A1HPGDHSD17B10TDP1 | |
| SCHEMBL24104 | 0.71 | HPRT1 (0.35) | CYP1A2ALDH1A1HPGDHSD17B10TDP1 | |
| SCHEMBL2407351 | 0.71 | HPRT1 (0.35) | CYP1A2ALDH1A1HPGDHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216414-A1 | Method for preventing tissue injury from hypoxia | CELL THERAPEUTICS,INC. | 2003-11-20 | — | — | US | claimed |
| US-6638938-B1 | By tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic | CELL THERAPEUTICS, INC. | 2003-10-28 | — | — | US | claimed |
| EP-0739203-A4 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS INC (US) | 2000-12-20 | — | — | EP | claimed |
| US-5985926-A | VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS | CELL THERAPEUTICS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| US-5856331-A | LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR | CELL THERAPEUTICS, INC. (US) | 1999-01-05 | — | — | US | claimed |
| EP-0739203-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1996-10-30 | — | — | EP | claimed |
| EP-0728003-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1996-08-28 | — | — | EP | claimed |
| EP-0676958-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | claimed |
| WO-1995013075-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1995-05-18 | — | — | WO | claimed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | claimed |
| CN-117736245-A | Organometallic compound, organic light-emitting device, electronic apparatus, and consumer product | 三星显示有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-113766914-B | Pentaneamidine analogues and uses thereof | 美商奥润沙公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117430589-A | 2-aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-0676958-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995019171-A1 | METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF | CELL THERAPEUTICS, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
| WO-1995013808-A1 | METHOD FOR SELECTIVELY INHIBITING IL-2 SIGNAL TRANSDUCTION | CELL THERAPEUTICS, INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995013075-A1 | METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA | CELL THERAPEUTICS, INC. (US) | 1995-05-18 | — | — | WO | disclosed |
| WO-1995012396-A1 | METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION | CELL THERAPEUTICS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | FCGRT, MSN, FCGR3B | GPR3 4112/4885LMNA 1233/4885HTT 1080/4885 |
| US-20030216414-A1 | Method for preventing tissue injury from hypoxia | HIF1AN, LPCAT3, PLAAT2 | GPR3 2732/4885LMNA 625/4885HTT 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.